USP Drug Classification

[ Brite menu | Download htext ]
    

1st Level  2nd Level  3rd Level  4th Level 

 Analgesics
 
 Anesthetics
 
 Anti-Addiction/Substance Abuse Treatment Agents
 
 Antibacterials
 
 Anticonvulsants
 
 Antidementia Agents
 
 Antidepressants
 
 Antiemetics
 
 Antifungals
 
 Antigout Agents
 
 Anti-inflammatory Agents
 
 Antimigraine Agents
 
 Antimyasthenic Agents
 
 Antimycobacterials
 
 Antineoplastics
 
 Antiparasitics
 
 Antiparkinson Agents
 
 Antipsychotics
 
 Antispasticity Agents
 
 Antivirals
 
 Anxiolytics
 
 Bipolar Agents
 
 Blood Glucose Regulators
 
 Blood Products/Modifiers/Volume Expanders
 
 Cardiovascular Agents
 
 Central Nervous System Agents
   Attention Deficit Hyperactivity Disorder Agents, Amphetamines
   Attention Deficit Hyperactivity Disorder Agents, Non- amphetamines
   Fibromyalgia Agents
   Multiple Sclerosis Agents
     Interferon beta-1a
     Interferon beta-1b
     Dalfampridine
     Teriflunomide
     Fingolomid
     Dimethyl fumarate
     Glatiramer
     Mitoxantrone
     Natalizumab
       D06886  Natalizumab (INN)
   Central Nervous System, Other
 
 Dental and Oral Agents
 
 Dermatological Agents
 
 Enzyme Replacement/Modifiers
 
 Gastrointestinal Agents
 
 Genitourinary Agents
 
 Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
 
 Hormonal Agents, Stimulant/Replacement/Modifying (Pituitary)
 
 Hormonal Agents, Stimulant/Replacement/Modifying (Prostaglandins)
 
 Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
 
 Hormonal Agents, Stimulant/Replacement/Modifying (Thyroid)
 
 Hormonal Agents, Suppressant (Adrenal)
 
 Hormonal Agents, Suppressant (Parathyroid)
 
 Hormonal Agents, Suppressant (Pituitary)
 
 Hormonal Agents, Suppressant (Thyroid)
 
 Immunological Agents
   Angioedema (HAE) Agents
   Immune Suppressants
   Immunizing Agents, Passive
   Immunomodulators
     Belimumab
     Interferon gamma-1b, Recombinant
     Canakinumab
     Rilonacept
     Tocilizumab
     Auranofin
     Leflunomide
     Natalizumab
       D06886  Natalizumab (INN)
   Vaccines
 
 Inflammatory Bowel Disease Agents
 
 Metabolic Bone Disease Agents
 
 Ophthalmic Agents
 
 Otic Agents
 
 Respiratory Tract/Pulmonary Agents
 
 Skeletal Muscle Relaxants
 
 Sleep Disorder Agents
 
 Therapeutic Nutrients/Minerals/Electrolytes

[ DRUG | BRITE | KEGG2 | KEGG ]
Last updated: March 26, 2014
According to the USP Medicare Model Guidelines v6.0

» Japanese version